By Lewis Krauskopf NEW YORK (Reuters) -Investors are turning their focus to Tuesday’s U.S. midterm elections, which will determine control…
Novavax says Omicron shot shows strong immune response as second booster
(Reuters) – Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a…
Bayer beats Q3 profit forecast on strong herbicide sales
By Ludwig Burger FRANKFURT (Reuters) -Agriculture and pharmaceuticals company Bayer on Tuesday reported better-than-expected quarterly earnings as higher prices for…
New Swedish govt cuts fuel taxes, boosts defence in first budget
By Simon Johnson STOCKHOLM (Reuters) -Sweden’s new right-wing government outlined cuts to fuel taxes and higher spending on defence, welfare…
BioNTech executive says it is too early to predict China vaccine approval
FRANKFURT (Reuters) – A BioNTech executive on Monday confirmed that the company is in discussions with Chinese authorities over regulatory…
FDA staff flags uncertainties on Veru’s COVID drug; EUA hopes lift shares
By Bhanvi Satija (Reuters) – Staff reviewers at the U.S. Food and Drug Administration on Monday identified several uncertainties around…
Walgreens-backed VillageMD to buy Summit Health in $9 billion deal
By Leroy Leo (Reuters) – Primary care provider VillageMD, which is backed by Walgreens Boots Alliance Inc, is buying urgent…
Gilead, Kite in process of pausing Twitter advertising
(Reuters) – Gilead Sciences Inc said on Monday the company and its unit Kite were in the “process of pausing…
U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead
By Blake Brittain WASHINGTON (Reuters) -The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co’s Juno…
FACTBOX-Australia Inc roiled by raft of cyberattacks this year
(Reuters) -Australian firms have suffered a flood of cyberattacks, putting the spotlight on country’s understaffed cybersecurity industry which experts say…